The Impact of Glucagon-Like Peptide-1 Receptor Agonist on the Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis and Systematic Review.
糖尿病患者中胰高血糖素樣肽-1受體激動劑對心血管結果的影響:一項荟萃分析和系統性回顧。
Cardiol Res 2023-08-11
Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data.
GLP-1/GIP 受體共激動劑用於心臟保護、2型糖尿病和肥胖:機制和臨床數據綜述。
Curr Opin Cardiol 2023-11-02
Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiovascular Risk Management in Patients With Type 2 Diabetes Mellitus: A Systematic Review.
GLP-1受體激動劑在第2型糖尿病患者心血管風險管理中的作用:系統性回顧。
Cureus 2023-10-21
The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action.
GLP-1受體激動劑在肥胖和2型糖尿病之外對心血管的影響:抗動脈粥樣硬化作用。
Trends Cardiovasc Med 2024-04-23
Glucagon-like peptide-1 receptor agonists: new strategies and therapeutic targets to treat atherosclerotic cardiovascular disease.
葡萄糖樣肽-1 受體激動劑:治療動脈粥樣硬化心血管疾病的新策略和治療靶點。
Front Pharmacol 2024-05-10
Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs.
GLP-1 受體激動劑的心血管保護特性:不僅僅是糖尿病和減重藥物。
J Clin Med 2024-08-29